182 related articles for article (PubMed ID: 34661159)
21. Skp2 promotes APL progression through the stabilization of oncoprotein PML-RARα and the inhibition of JunB expression.
Dan W; Zhong L; Yu L; Xiong L; Li J; Ye J; Luo X; Liu C; Chu X; Liu B
Life Sci; 2022 Jan; 289():120231. PubMed ID: 34921867
[TBL] [Abstract][Full Text] [Related]
22. Caspases mediate retinoic acid-induced degradation of the acute promyelocytic leukemia PML/RARalpha fusion protein.
Nervi C; Ferrara FF; Fanelli M; Rippo MR; Tomassini B; Ferrucci PF; Ruthardt M; Gelmetti V; Gambacorti-Passerini C; Diverio D; Grignani F; Pelicci PG; Testi R
Blood; 1998 Oct; 92(7):2244-51. PubMed ID: 9746761
[TBL] [Abstract][Full Text] [Related]
23. Altered ligand binding and transcriptional regulation by mutations in the PML/RARalpha ligand-binding domain arising in retinoic acid-resistant patients with acute promyelocytic leukemia.
Côté S; Zhou D; Bianchini A; Nervi C; Gallagher RE; Miller WH
Blood; 2000 Nov; 96(9):3200-8. PubMed ID: 11050004
[TBL] [Abstract][Full Text] [Related]
24. [Basic and clinical studies of the gene product-targeting therapy based on leukemogenesis--editorial].
Chen SJ; Chen LJ; Zhou GB
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Feb; 13(1):1-8. PubMed ID: 15748426
[TBL] [Abstract][Full Text] [Related]
25. RXRα ligand Z-10 induces PML-RARα cleavage and APL cell apoptosis through disrupting PML-RARα/RXRα complex in a cAMP-independent manner.
Xu L; Zeng Z; Zhang W; Ren G; Ling X; Huang F; Xie P; Su Y; Zhang XK; Zhou H
Oncotarget; 2017 Feb; 8(7):12311-12322. PubMed ID: 28129653
[TBL] [Abstract][Full Text] [Related]
26. TRIB3 Promotes APL Progression through Stabilization of the Oncoprotein PML-RARα and Inhibition of p53-Mediated Senescence.
Li K; Wang F; Cao WB; Lv XX; Hua F; Cui B; Yu JJ; Zhang XW; Shang S; Liu SS; Yu JM; Han MZ; Huang B; Zhang TT; Li X; Jiang JD; Hu ZW
Cancer Cell; 2017 May; 31(5):697-710.e7. PubMed ID: 28486108
[TBL] [Abstract][Full Text] [Related]
27. Novel mutation in the PML/RARalpha chimeric gene exhibits dramatically decreased ligand-binding activity and confers acquired resistance to retinoic acid in acute promyelocytic leukemia.
Takayama N; Kizaki M; Hida T; Kinjo K; Ikeda Y
Exp Hematol; 2001 Jul; 29(7):864-72. PubMed ID: 11438209
[TBL] [Abstract][Full Text] [Related]
28. In vitro inhibition of promyelocytic leukemia/retinoic acid receptor-alpha (PML/RARalpha) expression and leukemogenic activity by DNA/LNA chimeric antisense oligos.
Caprodossi S; Galluzzi L; Biagetti S; Della Chiara G; Pelicci PG; Magnani M; Fanelli M
Oncol Res; 2005; 16(3):157-66. PubMed ID: 16925116
[TBL] [Abstract][Full Text] [Related]
29. Molecular analysis and clinical outcome of adult APL patients with the type V PML-RARalpha isoform: results from intergroup protocol 0129.
Slack JL; Willman CL; Andersen JW; Li YP; Viswanatha DS; Bloomfield CD; Tallman MS; Gallagher RE
Blood; 2000 Jan; 95(2):398-403. PubMed ID: 10627441
[TBL] [Abstract][Full Text] [Related]
30. PIC-1/SUMO-1-modified PML-retinoic acid receptor alpha mediates arsenic trioxide-induced apoptosis in acute promyelocytic leukemia.
Sternsdorf T; Puccetti E; Jensen K; Hoelzer D; Will H; Ottmann OG; Ruthardt M
Mol Cell Biol; 1999 Jul; 19(7):5170-8. PubMed ID: 10373566
[TBL] [Abstract][Full Text] [Related]
31. Arsenic but not all-trans retinoic acid overcomes the aberrant stem cell capacity of PML/RARalpha-positive leukemic stem cells.
Zheng X; Seshire A; Rüster B; Bug G; Beissert T; Puccetti E; Hoelzer D; Henschler R; Ruthardt M
Haematologica; 2007 Mar; 92(3):323-31. PubMed ID: 17339181
[TBL] [Abstract][Full Text] [Related]
32. Transcription therapy for acute promyelocytic leukaemia.
Douer D
Expert Opin Investig Drugs; 2000 Feb; 9(2):329-46. PubMed ID: 11060680
[TBL] [Abstract][Full Text] [Related]
33. Altered nuclear cofactor switching in retinoic-resistant variants of the PML-RARα oncoprotein of acute promyelocytic leukemia.
Farris M; Lague A; Manuelyan Z; Statnekov J; Francklyn C
Proteins; 2012 Apr; 80(4):1095-109. PubMed ID: 22228505
[TBL] [Abstract][Full Text] [Related]
34. Identification of a point mutation PML
Zhao S; Shi P; Zhong Q; Shao S; Huang Y; Sun Y; Wu C; Zhu HH
Biochem Biophys Res Commun; 2019 Apr; 511(3):518-523. PubMed ID: 30824184
[TBL] [Abstract][Full Text] [Related]
35. Feasibility and clinical significance of real-time quantitative RT-PCR assay of PML-RARalpha fusion transcript in patients with acute promyelocytic leukemia.
Gu BW; Hu J; Xu L; Yan H; Jin WR; Zhu YM; Zhao WL; Niu C; Cao Q; Su XY; Gu J; Ying HY; Chen Y; Xiong SM; Shen ZX; Chen Z; Chen SJ
Hematol J; 2001; 2(5):330-40. PubMed ID: 11920269
[TBL] [Abstract][Full Text] [Related]
36. Blockade of deubiquitinase YOD1 degrades oncogenic PML/RAR
Shao X; Chen Y; Wang W; Du W; Zhang X; Cai M; Bing S; Cao J; Xu X; Yang B; He Q; Ying M
Acta Pharm Sin B; 2022 Apr; 12(4):1856-1870. PubMed ID: 35847510
[TBL] [Abstract][Full Text] [Related]
37. Molecular mechanisms of the antileukemia activities of retinoid and arsenic.
Nitto T; Sawaki K
J Pharmacol Sci; 2014; 126(3):179-85. PubMed ID: 25319615
[TBL] [Abstract][Full Text] [Related]
38. Response to histone deacetylase inhibition of novel PML/RARalpha mutants detected in retinoic acid-resistant APL cells.
Côté S; Rosenauer A; Bianchini A; Seiter K; Vandewiele J; Nervi C; Miller WH
Blood; 2002 Oct; 100(7):2586-96. PubMed ID: 12239173
[TBL] [Abstract][Full Text] [Related]
39. Relapse of acute promyelocytic leukemia with PML-RARalpha mutant subclones independent of proximate all-trans retinoic acid selection pressure.
Gallagher RE; Schachter-Tokarz EL; Zhou DC; Ding W; Kim SH; Sankoorikal BJ; Bi W; Livak KJ; Slack JL; Willman CL
Leukemia; 2006 Apr; 20(4):556-62. PubMed ID: 16437139
[TBL] [Abstract][Full Text] [Related]
40. Missense mutations in the PML/RARalpha ligand binding domain in ATRA-resistant As(2)O(3) sensitive relapsed acute promyelocytic leukemia.
Marasca R; Zucchini P; Galimberti S; Leonardi G; Vaccari P; Donelli A; Luppi M; Petrini M; Torelli G
Haematologica; 1999 Nov; 84(11):963-8. PubMed ID: 10553155
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
